Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.62 ^DKK	+1.85%		+5.08%	-8.82%

Feb. 29	Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Third Quarter Report Q3-2023

November 16, 2023 at 02:31 am EST

Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 1 July - 30 September 2023. The third quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.

Highlights Q3-2023 Report

Third quarter financial results 2023 (1 July - 30 September):

Net revenue was KDKK 0
Operating result was KDKK -5.811
Net result was KDKK -6.609
Cash at bank end of the period was KDKK 5.192
Earnings per share* was KDKK -0,48
Solidity** was 66%

The Company has advanced well with its planned activities

Last participant dosed in pivotal trail 0205
Agreement with EMA on PIP for CT002
Loan facility agreement to support US launch of CT001
US planning & preparation CT001 launch
Finalization of Study 0202 with competent authorities in selected countries

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 September 2023
amounted to 13.788.755 shares, the average number of shares during the second quarter was 13.788.755.
**Solidity: Total equity divided by total capital and liability

Comment from CEO, Jes Trygved: We were pleased to have the last participant enrolled in the pivotal study 0205 during Q3 2023. This was an important milestone for the Company, and we look forward to presenting top-line results towards the end of the year. In addition, our Paediatric Investigation plan for CT002 was agreed with the European regulatory authorities, allowing us to initiate development of this second asset in our pipeline. Our focus is also very much on the planning and preparation for the US launch of CT001 where we expect to book our first income already in 2024. To have a marketed product available for patients in just three years since the company was founded is impressive and I would like to thank the team for its efficiency, hard work and commitment for making this possible.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.

https://news.cision.com/cessatech/r/third-quarter-report-q3-2023,c3876676

https://mb.cision.com/Main/19921/3876676/2433199.pdf

Latest news about Cessatech A/S

Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	23-10-25	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	23-09-21	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	23-09-12	MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	23-09-12	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001	23-08-17	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	23-06-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-29	CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board	23-03-23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Cessatech to Raise $2 Million in Rights Offer	22-11-14	MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	22-09-23	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	22-09-05	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	22-06-30	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	22-05-16	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Cessatech A/S Announces Board Changes	22-03-17	CI
Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001	22-03-08	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI

Chart Cessatech A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data